The coronary drug eluting stent market is currently valued at $3.8 billion in 2022 and is anticipated to experience a compounded annual growth rate (CAGR) of 9.26% throughout the forecast period. Cardiovascular diseases (CVD) constitute a prominent global health challenge, ranking among the primary causes of mortality worldwide, outpacing conditions such as cancer and respiratory disorders. The World Health Organization (WHO) reports that cardiac disorders are responsible for approximately one-third of the annual global deaths, totaling an estimated 18 million fatalities. Notably, coronary artery disease (CAD) stands out as the most prevalent form of cardiovascular disorder, contributing to around 11 million deaths in 2020. The onset of the pandemic in the same year resulted in a notable over 3% increase in deaths attributed to heart diseases.

According to the Centers for Disease Control and Prevention (CDC), the economic impact associated with cardiovascular diseases, encompassing annual medical costs and productivity loss, is anticipated to exceed $1,000 billion by 2030. Addressing the critical consequences of vessel narrowing and plaque accumulation in arteries involves the utilization of various coronary interventional devices. Among these, coronary drug-eluting stents (DES) have emerged as a favored solution.

Traditionally, bare-metal stents (BMS) were extensively employed to open blocked passages and restore proper blood flow to the heart. However, a shift in preference has been witnessed in recent years, with an increasing inclination towards drug-eluting stents (DES). These stents are coated with a polymer containing an antiproliferative drug, showcasing effectiveness in reducing or preventing in-stent restenosis, a significant complication associated with bare-metal stents. Considered revolutionary in interventional cardiology, cardiac stents enhance revascularization rates and diminish the risk of thrombosis.

Currently, the market offers more than 90 cardiovascular drug-eluting stents from approximately 40 global players, with the majority utilizing metals like platinum chromium and stainless steel. Notably, patents in this domain have experienced a compound annual growth rate (CAGR) of 13% over the past two decades. Innovations in cardiovascular therapeutics have been remarkable, including the development of advanced bioresorbable stents, drug combinations, and polymer and nanomaterial coatings aimed at improving safety and efficacy. Noteworthy is a recent proposal for an implantable biocompatible stent with miniaturized ultrasonic transducers for real-time monitoring of restenosis.

Moreover, recent strides in augmented reality and deep learning have the potential to facilitate the creation of patient-specific stents, paving the way for personalized treatment for individuals with cardiovascular disorders. Given the ongoing pace of innovation in the coronary drug-eluting stent market, coupled with the adoption of cutting-edge technologies by device developers, the increasing incidence of heart diseases, and the growing demand for related treatments, substantial growth is anticipated in the cardiovascular drug-eluting stent market during the forecast period.

Key Market Segments
Type of Drug Eluted
? Sirolimus
? Paclitaxel
? Everolimus
? Zotarolimus
? Others


Stent Material
? Platinum Chromium
? Cobalt Chromium
? Stainless Steel
? Others

Geographical Regions
? North America
? Europe
? Asia-Pacific
? MENA
? Latin America
? Rest of the World

Research Coverage:
? The report studies the coronary drug eluting stent market by type of drug eluted, stent material and key geographical regions.
? The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
? The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
? The report forecasts the revenue of market segments with respect to major regions.
? A comprehensive overview of companies engaged in the development and manufacturing of cardiovascular drug eluting stents, including details on their establishment year, company size, product range, and headquarters location. Additionally, an assessment of over 90 cardiovascular drug eluting stents based on parameters like eluted drug type, stent material, and various technical specifications.
? In-depth market trend analysis using five visual representations, including a heat map based on drug type and concentration, a stacked bar chart for drug and stent material, a tree map for stent dimensions, a 4D bubble chart comparing industry players, and a grid analysis based on multiple parameters.
? Company competitiveness analysis for cardiovascular drug eluting stent developers considering experience years and portfolio strength encompassing product variety, stent attributes, and more.
? Detailed profiles of prominent players in cardiovascular drug eluting stents, covering company background, employee count, headquarters location, executive team members, and their cardiovascular drug delivery device portfolio, along with recent developments and future prospects.
? An in-depth analysis of patents related to cardiovascular drug eluting stents, categorized by type, publication year, location, CPC symbols, applicant types, and leading industry/non-industry players, featuring three-dimensional bubble analysis, patent benchmarking, and valuation.
? A case study focusing on novel cardiovascular therapeutics and solutions, providing details about the developers, establishment years, company sizes, and headquarters locations.
? An extensive analysis estimating the current and future demand for cardiovascular drug eluting stents, based on parameters like eluted drug type, stent material, and geographical regions for the years 2022-2035, considering factors like the number of patients with cardiovascular disorders and average stent prices in different regions.

Key Benefits of Buying this Report
? The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
? Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
? The report provides stakeholders with a pulse on the container closure integrity testing market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
? You will get access to complimentary PPT insights and excel data packs / dynamic dashboards to easily navigate through complex analyses / charts.

Key Market Companies
? Alvimedica
? B. Braun
? Boston Scientific
? Cook Medical
? Eurocor Scientific
? Lepu Medical
? Medtronic
? Meril
? Relisys
? Sahajanand Medical Technologies